USPTO Examiner ALLEY GENEVIEVE S - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18795731COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2024October 2024Allow200YesNo
18795683COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2024October 2024Allow200YesNo
18795711COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2024October 2024Allow200YesNo
18758007COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAJune 2024December 2024Allow610NoNo
18444485Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereofFebruary 2024April 2025Allow1421NoNo
18443689NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSFebruary 2024May 2024Allow300YesNo
18430003NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSFebruary 2024January 2025Abandon1110NoNo
18421405LOSARTAN LIQUID FORMULATIONS AND METHODS OF USEJanuary 2024July 2024Allow610YesNo
18518100COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREANovember 2023February 2024Allow310NoNo
18518110COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREANovember 2023March 2024Allow400YesNo
18518093COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREANovember 2023April 2024Allow410NoNo
18490197COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAOctober 2023January 2024Allow200YesNo
18490188COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAOctober 2023January 2024Allow300YesNo
18470280COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERYSeptember 2023December 2024Allow1421NoNo
18448312COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2023January 2024Allow500YesNo
18448347COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2023October 2023Allow200YesNo
18448309COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2023October 2023Allow200YesNo
18448333COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2023September 2023Allow200YesNo
18229728ALUMINOSILICATE GLASS WITH PHOSPHORUS AND POTASSIUMAugust 2023June 2024Allow1121NoYes
18361981Dendritic Macroporous Hydrogels Prepared By Crystal TemplatingJuly 2023March 2024Allow710NoNo
18216890NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSJune 2023February 2024Allow710YesNo
18144800ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFRMay 2023February 2025Allow2110YesNo
18251929COMPOSITION FOR TREATING AND/OR PREVENTING FUNGAL INFECTIONSMay 2023December 2023Allow710YesNo
18246151COMPOSITIONS COMPRISING REACTION PRODUCTS OF SACCHARIDE POLYMERS AND FATTY ESTERS FORMULATED WITH A NEUTRAL SURFACTANTMarch 2023December 2023Allow910YesNo
18178789COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREAMarch 2023July 2023Allow510YesNo
18044015USE, IN AQUEOUS-ALCOHOLIC COMPOSITIONS, OF A COPOLYMER OBTAINED BY PRECIPITATION POLYMERIZATIONMarch 2023March 2025Abandon2430YesNo
18151846ONAPRISTONE EXTENDED-RELEASE COMPOSITIONS AND METHODSJanuary 2023November 2023Abandon1010NoNo
18094050AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOFJanuary 2023March 2024Allow1430YesNo
18148766COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREADecember 2022June 2023Allow510NoNo
18090582AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOFDecember 2022February 2024Allow1330YesNo
18089338AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOFDecember 2022February 2024Allow1430YesNo
18064222METHODS OF EFFICIENTLY TREATING VITAMIN C DEFICIENCY-RELATED DISEASES AND OTHER CONDITIONSDecember 2022May 2024Allow1730YesNo
17993422NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSNovember 2022November 2023Allow1120YesNo
18052116LOSARTAN LIQUID FORMULATIONS AND METHODS OF USENovember 2022December 2023Allow1321YesNo
18050951METHOD OF MANUFACTURING ANTIFOULING COATING POLYMER USING INITIATED CHEMICAL VAPOR DEPOSITIONOctober 2022May 2025Allow3120NoNo
18047964PROCESS FOR MESALAZINE SOLID FORMULATIONSOctober 2022October 2024Allow2410YesNo
18046778METHOD OF PREPARING NANOPARTICLES BY HOT-MELT EXTRUSIONOctober 2022December 2024Allow2620NoNo
17965633STABILIZING VITAMIN C TOPICAL FORMULATIONSOctober 2022June 2025Allow3241YesNo
17932453OPHTHALMIC FORMULATIONS OF METHOTREXATESeptember 2022March 2024Allow1821YesNo
17932426OPHTHALMIC FORMULATIONS OF METHOTREXATESeptember 2022March 2024Allow1821YesNo
17900953ANTIMICROBIAL GLASS COMPOSITIONS, GLASSES AND POLYMERIC ARTICLES INCORPORATING THE SAMESeptember 2022March 2025Abandon3110NoNo
17816486VALPROIC ACID FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATIONAugust 2022December 2024Allow2910NoNo
17866939AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOFJuly 2022February 2024Allow1941YesNo
17862421METHOD FOR PREPARING PEI-LIPID NANOPARTICLES USED FOR DELIVERING A MRNA VACCINE AND TRANSFECTING STEM CELLSJuly 2022October 2024Allow2710NoNo
17790808SOLUBLE MELATONIN TRIPARTATE ADDUCT FOR THE PREVENTION AND TREATMENT OF RARE AND SEVERE EYE SIGHT-THREATENING CONDITIONS AND NEURO-OPHTHALMIC DISORDERSJuly 2022March 2023Allow910YesNo
17843769ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFRJune 2022December 2022Allow600NoNo
17838364HAIR CARE COMPOSITIONS COMPRISING HYDROXYLATED TRIGLYCERIDE OLIGOMERSJune 2022May 2024Allow2320YesNo
17774845COMPOSITION WITH SUPERABSORBENT POLYMERMay 2022May 2025Allow3610YesNo
17735820COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREAMay 2022December 2022Allow710YesNo
17773995PYRIDYLOXYACETIC ACID COMPOUND AND USE OF SAMEMay 2022May 2025Allow3611YesNo
17722688ALUMINOSILICATE GLASS WITH PHOSPHORUS AND POTASSIUMApril 2022April 2023Allow1221YesYes
17715355PHOTOPROTECTIVE COMPOSITIONS COMPRISING A DIBENZOYLMETHANE DERIVATIVE, A MEROCYANINE COMPOUND AND A COMPOUND CAPABLE OF ACCEPTING THE TRIPLET EXCITED LEVEL ENERGY OF THE DIBENZOYLMETHANE COMPOUNDApril 2022November 2023Abandon1910NoNo
17692521SOFT GELATIN CAPSULES CONTAINING A MIXTURE OF ANALGESICS AND DECONGESTANTS, EXPECTORANTS, ANTITUSSIVES AND/OR ANTIHISTAMINESMarch 2022May 2023Allow1400YesNo
17686373SUSPENSION COMPONENT-SPECIFIC TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONS AND ASSOCIATED METHODS OF USEMarch 2022April 2022Allow100YesNo
17686371LIMITED PARTICLE SIZE TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONS AND ASSOCIATED METHODS OF USEMarch 2022May 2022Allow200YesNo
17686368MOXIFLOXACIN AND TRIAMCINOLONE COMPOSITIONS AND ASSOCIATED METHODSMarch 2022April 2022Allow100YesNo
17592700Choline EstersFebruary 2022March 2025Abandon3710NoNo
17591250INDANE DERIVATIVES FOR MALODOR COUNTERACTIONFebruary 2022November 2024Abandon3411NoNo
17590213Vaginal HydrogelFebruary 2022August 2023Allow1810YesNo
17584997ANTI-AGING DRUG COMBINATION AND USE THEREOFJanuary 2022September 2024Allow3211YesNo
17628021NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSJanuary 2022February 2025Abandon3710NoNo
17576943VETERINARY BROMHEXINE HYDROCHLORIDE SOLUBLE POWDER, PREPARATION METHOD AND USE THEREOFJanuary 2022January 2024Abandon2421NoNo
17547975OPHTHALMIC SHIELD AND THERAPEUTIC APPARATUSDecember 2021June 2025Allow4220YesNo
17544630Targeting MicrobubblesDecember 2021December 2022Allow1210YesNo
17615694STABLE MICROBICIDE COMPOSITIONDecember 2021May 2025Allow4250YesYes
17533461COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERYNovember 2021June 2023Allow1910YesNo
17455563DEFOAMER USEFUL IN A PERACID COMPOSITION WITH ANIONIC SURFACTANTSNovember 2021June 2025Allow4340YesNo
17595192ORGANIC ACID SALT OF NICOTINAMIDE RIBOSIDE, COMPOSITION INCLUDING ORGANIC ACID SALT, AND PREPARATION METHODS OF ORGANIC ACID SALT AND COMPOSITIONNovember 2021August 2022Allow900YesNo
17522548COMPOUNDS FOR PRENATAL TREATMENT COMPRISIING A NATAL VITAMIN AND ASPIRIN AND METHOD FOR MAKING AND USING THE SAMENovember 2021November 2023Abandon2510NoNo
17488061Methods and Formulations for Preventing Neurological or Psychiatric DisordersSeptember 2021August 2024Abandon3520NoNo
17479886GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISORDERSSeptember 2021September 2023Abandon2431YesNo
17477361LOW-BURST POLYMERS AND METHODS TO PRODUCE POLYMERSeptember 2021March 2023Allow1810NoNo
17474656Onychomycosis Treatment Compositions and MethodsSeptember 2021May 2022Allow811YesNo
17470891Taxane Analogs for the Treatment of Brain CancerSeptember 2021June 2023Allow2110NoNo
17467752CHITOOLIGOSACCHARIDES AND METHODS FOR USE IN ENHANCING PLANT GROWTHSeptember 2021September 2024Allow3630YesNo
17466189METHODS AND COMPOSITIONS FOR ANTIMICROBIAL TREATMENTSeptember 2021December 2023Allow2830YesNo
17458533PREDNISOLONE AND MOXIFLOXACIN COMPOSITIONS AND METHODSAugust 2021February 2024Allow3061YesNo
17458523TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONSAugust 2021December 2021Allow300YesNo
17393196FORMULATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITORSAugust 2021March 2025Abandon4321NoNo
17364199Long acting drug delivery device and its use in contraceptionJune 2021March 2025Allow4431YesNo
17361471PHARMACEUTICAL FORMULATION CONTAINING COMBINATION OF M3 ANTAGONIST-BETA-2 AGONIST AND INHALED CORTICOSTEROIDSJune 2021September 2022Abandon1420NoNo
17360852NITRIC OXIDE RELEASING PHARMACEUTICAL COMPOSITIONSJune 2021June 2024Abandon3621NoNo
17350110Use of short chain fatty acids for the treatment and prevention of diseases and disordersJune 2021April 2023Allow2210YesNo
17337095USE OF CYSTEAMINE AND DERIVATIVES THEREOF TO SUPPRESS TUMOR METASTASESJune 2021August 2023Allow2610NoNo
17336412PREVENTION OF THE WRINKLING AND EXPRESSION OF HUMAN SKINJune 2021January 2025Abandon4330NoNo
17335496D2O STABILIZED PHARMACEUTICAL FORMULATIONSJune 2021May 2024Allow3521NoNo
17335490D2O STABILIZED PHARMACEUTICAL FORMULATIONSJune 2021July 2024Allow3740YesNo
17327203ESLICARBAZEPINE SUSPENSIONMay 2021March 2022Allow1011YesNo
17321905ANTIMICROBIAL GLASS COMPOSITIONS, GLASSES AND POLYMERIC ARTICLES INCORPORATING THE SAMEMay 2021June 2022Allow1300YesNo
17322316COMPOSITIONS AND METHODS OF TREATING COGNITIVE IMPAIRMENTMay 2021November 2021Allow610YesNo
17316020ANTIMICROBIAL GLASS COMPOSITIONS, GLASSES AND POLYMERIC ARTICLES INCORPORATING THE SAMEMay 2021June 2022Allow1400YesNo
17313296METHODS OF MODULATING IMMUNE ACTIVITYMay 2021March 2022Allow1021YesNo
17307275METHODS AND COMPOSITIONS FOR TREATING MEIBOMIAN GLAND DYSFUNCTIONMay 2021November 2022Allow1830YesNo
17238869AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOFApril 2021March 2022Allow1121YesNo
17231653Dendritic Macroporous Hydrogels Prepared By Crystal TemplatingApril 2021July 2023Allow2720YesNo
17217760CETIRIZINE OPHTHALMIC COMPOSITIONSMarch 2021December 2022Abandon2040YesNo
17206226SOLID PHARMACEUTICAL TABLETMarch 2021March 2023Allow2410YesNo
17202238MIDODRINE HYDROCHLORIDE ORAL SOLUTION AND USES THEREOFMarch 2021March 2024Abandon3611NoNo
17192709COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERYMarch 2021September 2021Allow711YesNo
17188492METHODS FOR CANCER THERAPYMarch 2021November 2021Allow900YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALLEY, GENEVIEVE S.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
20
Examiner Affirmed
18
(90.0%)
Examiner Reversed
2
(10.0%)
Reversal Percentile
21.7%
Lower than average

What This Means

With a 10.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
70
Allowed After Appeal Filing
23
(32.9%)
Not Allowed After Appeal Filing
47
(67.1%)
Filing Benefit Percentile
47.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 32.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ALLEY, GENEVIEVE S - Prosecution Strategy Guide

Executive Summary

Examiner ALLEY, GENEVIEVE S works in Art Unit 1617 and has examined 746 patent applications in our dataset. With an allowance rate of 60.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.

Allowance Patterns

Examiner ALLEY, GENEVIEVE S's allowance rate of 60.6% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ALLEY, GENEVIEVE S receive 2.23 office actions before reaching final disposition. This places the examiner in the 76% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ALLEY, GENEVIEVE S is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +53.1% benefit to allowance rate for applications examined by ALLEY, GENEVIEVE S. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.1% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 30.5% of cases where such amendments are filed. This entry rate is in the 36% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 62.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 49% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 65.5% of appeals filed. This is in the 41% percentile among all examiners. Of these withdrawals, 55.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 51.6% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 47% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 48% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.